Roche Aktie [WKN: 855167 / ISIN: CH0012032048]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche AG (Genussschein)

07:00		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth (Roche Holding AG)
29.01.25		Change to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
28.01.25		Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer (Roche Holding AG)
27.01.25		Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) (Roche Holding AG)
22.01.25		Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care (Roche Holding AG)
08.01.25		Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (Roche Holding AG)
19.12.24		Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (Roche Holding AG)
18.12.24		Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (Roche Holding AG)
13.12.24		Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (Roche Holding AG)
10.12.24		New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (Roche Holding AG)
09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (Roche Holding AG)
26.11.24		Roche reports update on Phase III SKYSCRAPER-01 study results (Roche Holding AG)
05.11.24		Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
31.10.24		Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24		New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
23.10.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
18.10.24		Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
14.10.24		Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)
10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (Roche Holding AG)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (Roche Holding AG)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (Roche Holding AG)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (Roche Holding AG)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (Roche Holding AG)
29.07.24		Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (Roche Holding AG)
25.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter - full-year earnings outlook raised (Roche Holding AG)
18.07.24		New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (Roche Holding AG)
17.07.24		Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (Roche Holding AG)
17.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (Roche Holding AG)
09.07.24		Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (Roche Holding AG)
08.07.24		Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
05.07.24		FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (Roche Holding AG)
04.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (Roche Holding AG)
28.06.24		Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (Roche Holding AG)
28.06.24		CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (Roche Holding AG)
27.06.24		Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (Roche Holding AG)
25.06.24		Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (Roche Holding AG)
24.06.24		Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (Roche Holding AG)
20.06.24		Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (Roche Holding AG)
15.06.24		Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)

1 | Weiter

Newssuche

Roche Peer Group Nachrichten

10:54		Roche-Aktie kaum verändert: 2024 auf Wachstumskurs - Befreiung von Altlasten
10:18		Ausblick: Novartis legt Zahlen zum jüngsten Quartal vor
09:30		Donnerstagshandel in London: FTSE 100 zum Start leichter
09:30		Börse Zürich in Grün: SLI legt zum Start zu
09:30		Donnerstagshandel in Europa: Zum Start des Donnerstagshandels Gewinne im STOXX 50
09:30		Zuversicht in Zürich: SMI zum Start auf grünem Terrain
29.01.25		Schwacher Wochentag in New York: Dow Jones letztendlich in Rot
29.01.25		Dow Jones aktuell: Dow Jones gibt am Mittwochmittag nach

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.01.2025 11:53
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie [WKN: 855167 / ISIN: CH0012032048]

Nachrichten zu Roche AG (Genussschein)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten